##common.pageHeaderLogo.altText##

Original article

Vol. 155 No. 4 (2025)

Epidural dexamethasone-21-palmitate for spinal stenosis-related pain: a retrospective cohort study using patient-reported outcome data

Cite this as:
Swiss Med Wkly. 2025;155:4100
Published
10.04.2025

Summary

OBJECTIVE: Epidural steroid infiltration has been used for decades as symptomatic pain therapy. To record and evaluate treatment response to epidural steroid infiltration, patient-reported outcome data were collected from patients receiving interlaminar or transforaminal epidural steroid infiltration with dexamethasone-21-palmitate (Lipotalon®).

METHODS: This retrospective study included patient-reported outcome data from 212 patients who received treatment with translaminar or transforaminal epidural steroid infiltration at University Hospital Basel between July 2019 and April 2022. To evaluate pain and quality of life after treatment, the Numeric Rating Scale (NRS), Pain and Enjoyment of Life and General Activity (PEG) scale, European Quality of Life 5 Dimensions Questionnaire (EQ-5D-5L) and Oswestry Disability Index (ODI) were assessed prior to and at 7 days, one month and three months after treatment.

RESULTS: There was a significant decrease in back pain on the NRS at 7 days and 3 months post-intervention compared to admission: 6.07 (SD 2.27) at admission, 4.52 (SD 2.26) at 7 days and 4.21 (SD 2.69) at 3 months (all p-values <0.001). Similarly, a significant decrease could be reported for leg pain: 5.59 (SD 2.72) at admission, 3.89 (SD 2.64) at 7 days and 3.58 (SD 2.84) at 3 months (all p-values <0.001). The mean PEG scale was 6.34 (SD 1.84) at admission, 4.52 (SD 2.15) at 7 days and 3.93 (SD 2.6) at 3 months (all p-values <0.001). The mean ODI score also improved significantly: 35.67 (SD 15.75) at admission, 28.24 (SD 16.11) at 7 days and 25.17 (SD 16.22) at 3 months (all p-values <0.002). The mean EQ-5D-5L score did not differ significantly during the observation period.

CONCLUSIONS: Dexamethasone-21-palmitate may be a potential treatment alternative to traditional water-soluble steroids. However, further controlled trials are necessary to confirm the efficacy and safety of this treatment.

References

  1. Bundesamt für Statistik (BFS). Gesundheitsstatistik 2019.34. Available from: https://www.bfs.admin.ch/asset/de/10227275
  2. Patel EA, Perloff MD. Radicular Pain Syndromes: Cervical, Lumbar, and Spinal Stenosis. Semin Neurol. 2018;38(6):634-9. Epub 20181206. doi: 10.1055/s-0038-1673680.
  3. Tarulli AW, Raynor EM. Lumbosacral radiculopathy. Neurol Clin. 2007 May;25(2):387–405. 10.1016/j.ncl.2007.01.008
  4. Di Gangi S, Bagnoud C, Pichierri G, Rosemann T, Plate A. Characteristics and health care costs in patients with a diagnostic imaging for low back pain in Switzerland. Eur J Health Econ. 2022;23(5):823-35. Epub 20211030. doi: 10.1007/s10198-021-01397-8
  5. Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, et al.; American Pain Society Low Back Pain Guideline Panel. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline from the American Pain Society. Spine. 2009 May;34(10):1066–77. 10.1097/BRS.0b013e3181a1390d
  6. Frymoyer JW. Back pain and sciatica. N Engl J Med. 1988 Feb;318(5):291–300. 10.1056/nejm198802043180506 doi: https://doi.org/10.1056/NEJM198802043180506
  7. FDA Drug Safety Communication. FDA Drug Safety Communication: FDA requires label changes to warn of rare but serious neurologic problems after epidural corticosteroid injections for pain 2014 [1.05.2022]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-requires-label-changes-warn-rare-serious-neurologic-problems-after
  8. Dietrich TJ, Sutter R, Froehlich JM, Pfirrmann CW. Particulate versus non-particulate steroids for lumbar transforaminal or interlaminar epidural steroid injections: an update. Skeletal Radiol. 2015 Feb;44(2):149–55. 10.1007/s00256-014-2048-6
  9. Abraham G, Demiraj F, Ungemach FR. Comparison of the hypothalamic-pituitary-adrenal axis susceptibility upon single-dose i.m. depot versus long-acting i.v. triamcinolone acetonide therapy: a direct pharmacokinetic correlation. J Endocrinol. 2006 Nov;191(2):491–6. 10.1677/joe.1.06991
  10. Cohen SP, Ross JD. Lumbar transforaminal epidural steroid injections with particulate vs. nonparticulate steroid: an evidence-informed review on shifting gear to a personalized medicine paradigm. Curr Opin Anaesthesiol. 2024;37(5):565-74. Epub 20240611. doi: 10.1097/aco.0000000000001402 doi: https://doi.org/10.1097/ACO.0000000000001402
  11. House LM, Barrette K, Mattie R, McCormick ZL. Cervical Epidural Steroid Injection: techniques and Evidence. Phys Med Rehabil Clin N Am. 2018 Feb;29(1):1–17. 10.1016/j.pmr.2017.08.001
  12. Van Boxem K, Rijsdijk M, Hans G, de Jong J, Kallewaard JW, Vissers K, et al. Safe Use of Epidural Corticosteroid Injections: Recommendations of the WIP Benelux Work Group. Pain Pract. 2019;19(1):61-92. Epub 20180702. doi: 10.1111/papr.12709
  13. Swissmedic. Swissmedicinfo: Official medicinal product information. Available from: www.swissmedicinfo.ch
  14. Hodgson PS, Neal JM, Pollock JE, Liu SS. The neurotoxicity of drugs given intrathecally (spinal). Anesth Analg. 1999 Apr;88(4):797–809. 10.1213/00000539-199904000-00023
  15. Wakiguchi H, Ohga S. [Clinical utility of the liposteroid therapy: potential effects on the macrophage activation]. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):190–6. 10.2177/jsci.39.190
  16. Saha BK, Milman NT. Short Review of Liposteroid: A Novel Targeted Glucocorticoid Preparation for Treatment of Autoimmune and Inflammatory Diseases. Prague Med Rep. 2021;122(4):257–68. 10.14712/23362936.2021.23
  17. Weldring T, Smith SM. Patient-Reported Outcomes (PROs) and Patient-Reported Outcome Measures (PROMs). Health Serv Insights. 2013;6:61-8. Epub 20130804. doi: 10.4137/hsi.S11093 doi: https://doi.org/10.4137/HSI.S11093
  18. Australian Commission on Safety and Quality in Health Care. About PROMs 2023. Available from: https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/patient-reported-outcomes/about-proms
  19. Australian Commission on Safety and Quality in Health Care. Patient-reported outcome measures 2022. Available from: https://www.safetyandquality.gov.au/our-work/indicators-measurement-and-reporting/patient-reported-outcome-measures
  20. Hostettler S, Kraft E, Bosshard C, Patient-reported outcome mea­sures: Die Patientensicht zählt. Schweizerische Ärztezeitung. 2018 Oct 3;99(40):1348. doi: https://doi.org/10.4414/saez.2018.17187
  21. International Spine Intervention Society (Bogduk N, editor). ISIS Practice Guidelines for Spinal Diagnostic and Treatment Procedures. 2nd ed. Hinsdale, Chicago: International Spine Intervention Society; 2014.
  22. Heartbeat Medical. Outcome Measurement for Clinicians and Hospitals Heartbeat Medical. Available from: https://heartbeat-med.com/solutions/clinicians-hospitals/
  23. Krebs EE, Lorenz KA, Bair MJ, Damush TM, Wu J, Sutherland JM, et al. Development and initial validation of the PEG, a three-item scale assessing pain intensity and interference. J Gen Intern Med. 2009 Jun;24(6):733–8. 10.1007/s11606-009-0981-1
  24. Heartbeat Medical. EQ-5D-5L Fragebogen 2023. Available from: https://heartbeat-med.com/de/resources/eq-5d-5l/
  25. EuroQol Research Foundation. EQ-5D-5L User Guide 2019. Available from: https://euroqol.org/publications/user-guides
  26. Mannion AF, Junge A, Fairbank JC, Dvorak J, Grob D. Development of a German version of the Oswestry Disability Index. Part 1: cross-cultural adaptation, reliability, and validity. Eur Spine J. 2006;15(1):55-65. Epub 20050426. doi: 10.1007/s00586-004-0815-0
  27. Heartbeat Medical. Oswestry Disability Index (ODI). Available from: https://heartbeat-med.com/resources/oswestry-disability-index-odi/#anchor10
  28. Smith SM, Dworkin RH, Turk DC, McDermott MP, Eccleston C, Farrar JT, et al. Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. Pain. 2020 Nov;161(11):2446–61. 10.1097/j.pain.0000000000001952
  29. Bartley EJ, Fillingim RB. Sex differences in pain: a brief review of clinical and experimental findings. Br J Anaesth. 2013 Jul;111(1):52–8. 10.1093/bja/aet127
  30. Meyer VM, Benjamens S, Moumni ME, Lange JF, Pol RA. Global Overview of Response Rates in Patient and Health Care Professional Surveys in Surgery: A Systematic Review. Ann Surg. 2022 Jan;275(1):e75–81. 10.1097/sla.0000000000004078 doi: https://doi.org/10.1097/SLA.0000000000004078
  31. Ahadian FM, McGreevy K, Schulteis G. Lumbar transforaminal epidural dexamethasone: a prospective, randomized, double-blind, dose-response trial. Reg Anesth Pain Med. 2011;36(6):572–8. 10.1097/AAP.0b013e318232e843
  32. Park CH, Jang YH, Lee SH. Comparison of Pain Reduction and Changes in Serum Cortisol and Glucose Levels to Different Doses of Lumbar Epidural Dexamethasone: A Prospective Study. Pain Physician. 2022 Oct;25(7):E1081–5.
  33. Shermon S, Van Acker G, Suric V, Kim C, Abd-Elsayed A, Mata N. Flushing After Lumbar Epidural Steroid Injection with Dexamethasone. Curr Pain Headache Rep. 2023 Jun;27(6):143–8. 10.1007/s11916-023-01117-2
  34. Fischer M, Kim PY. Corticosteroid-Induced Psychosis After a Single Transforaminal Epidural Steroid Injection. WMJ. 2019 Jul;118(2):91–4.